Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
Mak AL, Lee J, van Dijk AM, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Mak AL, et al. Among authors: schattenberg jm. Biomedicines. 2021 Dec 15;9(12):1920. doi: 10.3390/biomedicines9121920. Biomedicines. 2021. PMID: 34944736 Free PMC article. Review.
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. McPherson S, et al. Among authors: schattenberg jm. Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11. Am J Gastroenterol. 2017. PMID: 27725647 Free PMC article.
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.
Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H. Isokuortti E, et al. Among authors: schattenberg jm. Diabetologia. 2017 Oct;60(10):1873-1882. doi: 10.1007/s00125-017-4340-1. Epub 2017 Jun 29. Diabetologia. 2017. PMID: 28660493
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. Among authors: schattenberg jm. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 Free article.
Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation.
Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-Gómez M, Anstee QM, Schattenberg JM; EPoS Consortium Investigators. Huber Y, et al. Among authors: schattenberg jm. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1. doi: 10.1016/j.cgh.2018.12.016. Epub 2018 Dec 20. Clin Gastroenterol Hepatol. 2019. PMID: 30580090
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ. Harrison SA, et al. Among authors: schattenberg jm. J Hepatol. 2020 May;72(5):816-827. doi: 10.1016/j.jhep.2019.11.024. Epub 2019 Dec 27. J Hepatol. 2020. PMID: 31887369 Clinical Trial.
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Taylor RS, et al. Among authors: schattenberg jm. Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4. Gastroenterology. 2020. PMID: 32027911 Free article.
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.
Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Boyle M, et al. Among authors: schattenberg jm. JHEP Rep. 2019 Jul 4;1(3):188-198. doi: 10.1016/j.jhepr.2019.06.004. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039369 Free PMC article.
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. Eslam M, et al. Among authors: schattenberg jm. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278004 Free article. Review.
293 results